916056-79-6
Chemical Structure
Reproxalap
Synonym(s): ADX-102; NS-2
- CAS No.: 916056-79-6
- Formula:C12H13ClN2O
- Molecular Weight:236.70
IUPAC Name: 2-(3-amino-6-chloroquinolin-2-yl)propan-2-ol
InChIKey: GUHFUVLKYSQIOQ-UHFFFAOYSA-N
SMILES: CC(C1=NC2=C(C=C(Cl)C=C2)C=C1N)(O)C
Biological Activity: Reproxalap (ADX-102) is an active aldehyde sequestering agent. Reproxalap reduces the PKCα activity. Reproxalap blocks caspase 3/7 activation. Reproxalap protects cells from the cytotoxicity of C18:0-al. Reproxalap has anti-inflammatory and pain-relieving effects. Reproxalap is used in studies of dry eye, allergic conjunctivitis, and non-infectious anterior uveitis[1][2][3][4][5].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Reproxalap | 98.49% | Reproxalap (ADX-102) is an active aldehyde sequestering agent. Reproxalap reduces the PKCα activity. Reproxalap blocks caspase 3/7 activation. Reproxalap protects cells from the cytotoxicity of C18:0-al. Reproxalap has anti-inflammatory and pain-relieving effects. Reproxalap is used in studies of dry eye, allergic conjunctivitis, and non-infectious anterior uveitis. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Reproxalap (Standard) | Reproxalap (Standard) (ADX-102 (Standard)) is the analytical standard of Reproxalap (HY-107150). This product is intended for research and analytical applications. Reproxalap (ADX-102) is an active aldehyde sequestering agent. Reproxalap reduces the PKCα activity. Reproxalap blocks caspase 3/7 activation. Reproxalap protects cells from the cytotoxicity of C18:0-al. Reproxalap has anti-inflammatory and pain-relieving effects. Reproxalap is used in studies of dry eye, allergic conjunctivitis, and non-infectious anterior uveitis. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Ochoa CA, et al. Aldehyde Trapping by ADX-102 Is Protective against Cigarette Smoke and Alcohol Mediated Lung Cell Injury. Biomolecules. 2022 Mar 2;12(3):393. [Content Brief]
- [2]. Rizzo WB, et al. Sjögren-Larsson syndrome: A biochemical rationale for using aldehyde-reactive therapeutic agents. Mol Genet Metab Rep. 2021 Dec 23;30:100839. [Content Brief]
- [3]. Susan Macdonald, et al. ADX-102, a novel aldehyde trap, reduces nociceptive behavior in mouse models of carrageenan and CFA induced pain.
- [4]. Reproxalap Phase 2b Dry Eye Disease Results.
- [5]. Susan G. Macdonald, Ph.D., et al. Novel Small Molecule Aldehyde Sequestering Agents Demonstrate Broad Therapeutic Potential for Ocular Inflammation.
Keywords
